Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors

Drug Resistance Updates

Volumn 20, Issue , 2015, Pages 12-28

  Juchum, Michael ^a   Günther, Marcel ^a   Laufer, Stefan A ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

EGFR; Inhibitors; Mutation; NSCLC; Resistance

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; HM 61713; IBRUTINIB; ICOTINIB; MERELETINIB; MIDOSTAURIN; N [3 [[5 CHLORO 2 [[2 METHOXY 4 (4 METHYL 1 PIPERAZINYL)PHENYL]AMINO] 4 PYRIMIDINYL]OXY]PHENYL]ACRYLAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; ROCILETINIB; UNCLASSIFIED DRUG; [2 [[5 CHLORO 2 [[4 [4 (DIMETHYLAMINO) 1 PIPERIDINYL] 2 METHOXYPHENYL]AMINO] 4 PYRIMIDINYL]AMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; MUTANT PROTEIN; PROTEIN KINASE INHIBITOR;

CANCER GENETICS; CANCER PATIENT; CANCER RESISTANCE; DIARRHEA; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG TREATMENT FAILURE; EGFR GENE; FATIGUE; GENE MUTATION; GENE SEQUENCE; GENOME; HUMAN; LUNG ADENOCARCINOMA; MANTLE CELL LYMPHOMA; NAUSEA; NON SMALL CELL LUNG CANCER; NONHUMAN; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; RECEPTOR GENE; REVIEW; SKIN EXFOLIATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; MUTATION; PROCEDURES;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTANT PROTEINS; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84930754135     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2015.05.002     Document Type: Review

References (171)

1. X. Ai, Y. Sun, H. Wang, and S. Lu A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity Amino Acids 46 2014 1635 1648
2. M.E. Arcila, G.R. Oxnard, K. Nafa, G.J. Riely, S.B. Solomon, M.F. Zakowski, M.G. Kris, W. Pao, V.A. Miller, and M. Ladanyi Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay Clin. Cancer Res. 17 2011 1169 1180
3. H. Asahina, K. Yamazaki, I. Kinoshita, N. Sukoh, M. Harada, H. Yokouchi, T. Ishida, S. Ogura, T. Kojima, Y. Okamoto, Y. Fujita, H. Dosaka-Akita, H. Isobe, and M. Nishimura A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations Br. J. Cancer 95 2006 998 1004
4. Y.G. Assaraf The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis Drug Resist. Updat. 9 2006 227 246
5. S. Atagi, N. Katakami, T. Hida, K. Goto, T. Horai, A. Inoue, A. Sarashina, Y. Seki, R. Lorence, M. Shahidi, and N. Yamamoto LUX-Lung 4: a phase II trial of afatinib (BIBW 2992) in advanced NSCLC patients previously treated with erlotinib or gefitinib J. Thorac. Oncol. 6 2011 360 361 (abstract)
6. L.R. Bailey, M. Janas, K. Schmidt, N. Bindslev, M. Wolf, J. Grous, J. Askaa, R. Herbst, D.H. Johnson, and G. Giaccone Evaluation of epidermal growth factor receptor (EGFR) as a predictive marker in patients with non-small-cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy J. Clin. Oncol. 22 2004 7013 (abstract)
7. Barker, A.J., Zeneca Ltd., 1993. Quinazoline tyrosine kinase-inhibiting anticancer agents. CA 2086968 A1 19930721.
8. Barker, A.J., Davies, D.H., Imperial Chemical Industries PLC, 1992. Preparation of 4-anilinoquinazolines as neoplasm inhibitors. EP 520722 A1 19921230.
9. A.J. Barker, K.H. Gibson, W. Grundy, A.A. Godfrey, J.J. Barlow, M.P. Healy, J.R. Woodburn, S.E. Ashton, B.J. Curry, L. Scarlett, L. Henthorn, and L. Richards Studies leading to the identification of ZD1839 (Iressa (TM)): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer Bioorg. Med. Chem. Lett. 11 2001 1911 1914
10. J. Baselga, D. Rischin, M. Ranson, H. Calvert, E. Raymond, D.G. Kieback, S.B. Kaye, L. Gianni, A. Harris, T. Bjork, S.D. Averbuch, A. Feyereislova, H. Swaisland, F. Rojo, and J. Albanell Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types J. Clin. Oncol. 20 2002 4292 4302
11. C. Bianco, G. Tortora, R. Bianco, R. Caputo, B.M. Veneziani, R. Caputo, V. Damiano, T. Troiani, G. Fontanini, D. Raben, S. Pepe, A.R. Bianco, and F. Ciardiello Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa) Clin. Cancer Res. 8 2002 3250 3258
12. M.L. Blackhall, R.G. Fassettl, J.E. Sharman, D.P. Geraghty, and J.S. Coombes Effects of antioxidant supplementation on blood cyclosporin A and glomerular filtration rate in renal transplant recipients Nephrol. Dial. Transplant. 20 2005 1970 1975
13. J.A. Blair, D. Rauh, C. Kung, C.H. Yun, Q.W. Fan, H. Rode, C. Zhang, M.J. Eck, W.A. Weiss, and K.M. Shokat Structure-guided development of affinity probes for tyrosine kinases using chemical genetics Nat. Chem. Biol. 3 2007 229 238
14. C.M. Blakely, and T.G. Bivona Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance Cancer Discov. 2 2012 872 875
15. M.J. Boyer, F.H. Blackhall, K. Park, C.H. Barrios, M.J. Krzakowski, I. Taylor, J.Q. Liang, L.J. Denis, J.P. O'Connell, and S.S. Ramalingam Efficacy and safety of PF299804 versus erlotinib (E): a global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT) J. Clin. Oncol. 28 2010 LBA7523 (abstract)
16. M.J. Boyer, P.A. Jänne, T. Mok, K.J. O'Byrne, L.G. Paz-Ares, S.S. Ramalingam, J.Q. Liang, I. Taylor, A. Campbell, J.P. O'Connell, S.P. Letrent, and V. Antic ARCHER: dacomitinib (D; PF-00299804) versus erlotinib (E) for advanced (adv) non-small cell lung cancer (NSCLC)-A randomized double-blind phase III study J. Clin. Oncol. 30 2012 TPS7615 (abstract)
17. S.R. Brave, R. Odedra, N.H. James, N.R. Smith, G.B. Marshall, K.L. Acheson, D. Baker, Z. Howard, L. Jackson, K. Ratcliffe, A. Wainwright, S.C. Lovick, D.M. Hickinson, R.W. Wilkinson, S.T. Barry, G. Speak, and A.J. Ryan Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer Int. J. Oncol. 39 2011 271 278
18. A.J. Bridges, H. Zhou, D.R. Cody, G.W. Rewcastle, A. McMichael, H.D.H. Showalter, D.W. Fry, A.J. Kraker, and W.A. Denny Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor J. Med. Chem. 39 1996 267 276
19. C.D. Britten, M. Pegram, P. Rosen, R.S. Finn, A. Wax, L. Bosserman, L. Gordon, L.S. Lin, R. Mass, and D.J. Slamon Targeting ErbB receptor interactions: a phase I trial of trastuzumab and erlotinib in metastatic HER2+ breast cancer J. Clin. Oncol. 22 2004 1335 1342
20. W. Brugger, and M. Thomas EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment Lung Cancer 77 2012 2 8
21. D.R. Camidge, L. Bazhenova, R. Salgia, G.J. Weiss, C.J. Langer, A.T. Shaw, N.I. Narasimhan, D.J. Dorer, V.M. Rivera, J. Zhang, T. Clackson, F.G. Haluska, and S.N. Gettinger First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: updated results J. Clin. Oncol. 31 2013 8031 (abstract)
22. S. Campos, O. Hamid, M.V. Seiden, A. Oza, M. Plante, R.K. Potkul, P.F. Lenehan, E.P. Kaldjian, M.L. Varterasian, C. Jordan, C. Charbonneau, and H. Hirte Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer J. Clin. Oncol. 23 2005 5597 5604
23. F. Carlomagno, D. Vitagliano, T. Guida, F. Ciardiello, G. Tortora, G. Vecchio, A.J. Ryan, G. Fontanini, A. Fusco, and M. Santor ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases Cancer Res. 62 2002 7284 7290
24. T.A. Carter, L.M. Wodicka, N.P. Shah, A.M. Velasco, M.A. Fabian, D.K. Treiber, Z.V. Milanov, C.E. Atteridge, W.H. Biggs, P.T. Edeen, M. Floyd, J.M. Ford, R.M. Grotzfeld, S. Herrgard, D.E. Insko, S.A. Mehta, H.K. Patel, W. Pao, C.L. Sawyers, H. Varmus, P.P. Zarrinkar, and D.J. Lockhart Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases Proc. Natl. Acad. Sci. U. S. A. 102 2005 11011 11016
25. V.D. Cataldo, D.L. Gibbons, R. Perez-Soler, and A. Quintas-Cardama Treatment of non-small-cell lung cancer with erlotinib or gefitinib N. Engl. J. Med. 364 2011 947 955
26. X.F. Chen, Q. Zhu, L.J. Zhu, D. Pei, Y.Q. Liu, Y.M. Yin, M. Schuler, and Y.Q. Shu Clinical perspective of afatinib in non-small cell lung cancer Lung Cancer 81 2013 155 161
27. C.R. Chong, and P.A. Jänne The quest to overcome resistance to EGFR-targeted therapies in cancer Nat. Med. 19 2013 1389 1400
28. M.H. Cohen, J.R. Johnson, Y.F. Chen, R. Sridhara, and R. Pazdur FDA drug approval summary: erlotinib (Tarceva (R)) tablets Oncologist 10 2005 461 466
29. D.A.E. Cross, S.E. Ashton, S. Ghiorghiu, C. Eberlein, C.A. Nebhan, P.J. Spitzler, J.P. Orme, M.R.V. Finlay, R.A. Ward, M.J. Mellor, G. Hughes, A. Rahi, V.N. Jacobs, M.R. Brewer, E. Ichihara, J. Sun, H. Jin, P. Ballard, K. Al-Kadhimi, R. Rowlinson, T. Klinowska, G.H.P. Richmond, M. Cantarini, D.-W. Kim, M.R. Ranson, and W. Pao AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer Cancer Discov. 4 2014 1046 1061
30. J.P. Delord, P. Beale, E. Van Cutsem, S. Clarke, C. Verslype, R. Bugat, A. Rakhit, S. Fettner, U. Brennscheidt, and A. Feyereislova A phase 1b dose-escalation trial of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer (MCRC) patients J. Clin. Oncol. 22 2004 3585 (abstract)
31. W.A. Denny, G.W. Rewcastle, A.J. Bridges, D.W. Fry, and A.J. Kraker Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitro Clin. Exp. Pharmacol. Physiol. 23 1996 424 427
32. J.A. Engelman, K. Zejnullahu, T. Mitsudomi, Y.C. Song, C. Hyland, J.O. Park, N. Lindeman, C.M. Gale, X.J. Zhao, J. Christensen, T. Kosaka, A.J. Holmes, A.M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B.E. Johnson, L.C. Cantley, and P.A. Jänne MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 2007 1039 1043
33. C. Erlichman, M. Hidalgo, J.P. Boni, P. Martins, S.E. Quinn, C. Zacharchuk, P. Amorusi, A.A. Adjei, and E.K. Rowinsky Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors J. Clin. Oncol. 24 2006 2252 2260
34. F.A.L.M. Eskens, C.H. Mom, A.S.T. Planting, J.A. Gietema, A. Amelsberg, H. Huisman, L. van Doorn, H. Burger, P. Stopfer, J. Verweij, and E.G.E. de Vries A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours Br. J. Cancer 98 2008 80 85
35. M.A. Fabian, W.H. Biggs, D.K. Treiber, C.E. Atteridge, M.D. Azimioara, M.G. Benedetti, T.A. Carter, P. Ciceri, P.T. Edeen, M. Floyd, J.M. Ford, M. Galvin, J.L. Gerlach, R.M. Grotzfeld, S. Herrgard, D.E. Insko, M.A. Insko, A.G. Lai, J.M. Lelias, S.A. Mehta, Z.V. Milanov, A.M. Velasco, L.M. Wodicka, H.K. Patel, P.P. Zarrinkar, and D.J. Lockhart A small molecule-kinase interaction map for clinical kinase inhibitors Nat. Biotechnol. 23 2005 329 336
36. C. Faivre-Finn, F. Blackhall, M. Snee, S. Harden, P. Hulse, and P. Lorigan Improving survival with thoracic radiotherapy in patients with small cell lung cancer. The CONVERT and the REST trials Clin. Oncol. 22 2010 547 549
37. Y. Fan, Z.Y. Huang, L. Fang, L.L. Miu, N.M. Lin, L. Gong, H.F. Yu, H.Y. Yang, and W.M. Mao Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients OncoTargets Ther. 6 2013 1789 1802
38. M.R.V. Finlay, M. Anderton, S. Ashton, P. Ballard, P.A. Bethel, M.R. Box, R.H. Bradbury, S.J. Brown, S. Butterworth, A. Campbell, C. Chorley, N. Colclough, D.A.E. Cross, G.S. Currie, M. Grist, L. Hassall, G.B. Hill, D. James, M. James, P. Kemmitt, T. Klinowska, G. Lamont, S.G. Lamont, N. Martin, H.L. McFarland, M.J. Mellor, J.P. Orme, D. Perkins, P. Perkins, G. Richmond, P. Smith, R.A. Ward, M.J. Waring, D. Whittaker, S. Wells, and G.L. Wrigley Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor J. Med. Chem. 57 2014 8249 8267
39. D.W. Fry, A.J. Kraker, A. Mcmichael, L.A. Ambroso, J.M. Nelson, W.R. Leopold, R.W. Conners, and A.J. Bridges A specific inhibitor of the epidermal growth-factor receptor tyrosine kinase Science 265 1994 1093 1095
40. D.W. Fry, J.M. Nelson, V. Slintak, P.R. Keller, G.W. Rewcastle, W.A. Denny, H.R. Zhou, and A.J. Bridges Biochemical and antiproliferative properties of 4-[ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor Biochem. Pharmacol. 54 1997 877 887
41. M. Fukuoka, Y.L. Wu, S. Thongprasert, P. Sunpaweravong, S.S. Leong, V. Sriuranpong, T.Y. Chao, K. Nakagawa, D.T. Chu, N. Saijo, E.L. Duffield, Y. Rukazenkov, G. Speake, H.Y. Jiang, A.A. Armour, K.F. To, J.C.H. Yang, and T.S.K. Mok Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) J. Clin. Oncol. 29 2011 2866 2874
42. M. Fukuoka, S. Yano, G. Giaccone, T. Tamura, K. Nakagawa, J.Y. Douillard, Y. Nishiwaki, J. Vansteenkiste, S. Kudoh, D. Rischin, R. Eek, T. Horai, K. Noda, I. Takata, E. Smit, S. Averbuch, A. Macleod, A. Feyereislova, R.P. Dong, and J. Baselga Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial) J. Clin. Oncol. 21 2003 2237 2246
43. K.S. Gajiwala, J.L. Feng, R. Ferre, K. Ryan, O. Brodsky, S. Weinrich, J.C. Kath, and A. Stewart Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition Structure 21 2013 209 219
44. H.K. Gan, A.N. Cvrljevic, and T.G. Johns The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered FEBS J. 280 2013 5350 5370
45. D.R. Gandara, T.H. Li, P.N. Lara, P.C. Mack, K. Kelly, S. Miyamoto, N. Goodwin, L. Beckett, and M.W. Redman Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity Clin. Lung Cancer 13 2012 321 325
46. W. Gao, M. Wang, L. Wang, H. Lu, S. Wu, B. Dai, Z. Ou, L. Zhang, J.V. Heymach, K.A. Gold, J. Minna, J.A. Roth, W.L. Hofstetter, S.G. Swisher, and B. Fang Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells J. Natl. Cancer Inst. 106 2014 1 4
47. Z. Gao, W. Chen, X. Zhang, P. Cai, X. Fang, Q. Xu, Y. Sun, and Y. Gu Icotinib, a potent and specific EGFR tyrosine kinase inhibitor, inhibits growth of squamous cell carcinoma cell line A431 through negatively regulating AKT signaling Biomed. Pharmacother. 67 2013 351 356
48. U. Gatzemeier, A. Pluzanska, A. Szczesna, E. Kaukel, J. Roubec, U. Brennscheidt, F. De Rosa, B. Mueller, J. Von Pawel, and T.S. Investigators Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) J. Clin. Oncol. 22 2004 7010 (abstract)
49. A.F. Gazdar Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors Oncogene 28 2009 24 31
50. A. Gazit, J. Chen, H. App, G. McMahon, P. Hirth, I. Chen, and A. Levitzki Tyrphostins IV - highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines Bioorg. Med. Chem. 4 1996 1203 1207
51. S.N. Gettinger, L. Bazhenova, R. Salgia, C.J. Langer, K.A. Gold, R. Rosell, A.T. Shaw, G.J. Weiss, N.I. Narasimhan, D.J. Dorer, V.M. Rivera, T. Clackson, F.G. Haluska, and D.R. Camidge Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC) J. Clin. Oncol. 32 2014 8047 (abstract)
52. G. Giaccone, R.S. Herbst, C. Manegold, G. Scagliotti, R. Rosell, V. Miller, R.B. Natale, J.H. Schiller, J. von Pawel, A. Pluzanska, M. Gatzemeier, J. Grous, J.S. Ochs, S.D. Averbuch, M.K. Wolf, P. Rennie, A. Fandi, and D.H. Johnson Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT1 J. Clin. Oncol. 22 2004 777 784
53. G. Giaccone, T. Lechevalier, N. Thatcher, E. Smit, M. Janmaat, J. Rodriguez, D. Oulid-Aissa, and J.C. Soria A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer J. Clin. Oncol. 23 2005 7076 (abstract)
54. M.M. Gottesman, T. Fojo, and S.E. Bates Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev. Cancer 2 2002 48 58
55. H. Greulich, T.-H. Chen, W. Feng, P.A. Jänne, J.V. Alvarez, M. Zappaterra, S.E. Bulmer, D.A. Frank, W.C. Hahn, W.R. Sellers, and M. Meyerson Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants PLoS Med. 2 2005 1167 1176
56. P.S. Hammerman, P.A. Jänne, and B.E. Johnson Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer Clin. Cancer Res. 15 2009 7502 7509
57. R.S. Herbst, G. Giaccone, J.H. Schiller, R.B. Natale, and V. Miller Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2 J. Clin. Oncol. 22 2004 785 794
58. R.S. Herbst, D.H. Johnson, E. Mininberg, D.P. Carbone, T. Henderson, E.S. Kim, G. Blumenschein, J.J. Lee, D.D. Liu, M.T. Truong, W.K. Hong, H. Tran, A. Tsao, D. Xie, D.A. Ramies, R. Mass, S. Seshagiri, D.A. Eberhard, S.K. Kelley, and A. Sandler Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer J. Clin. Oncol. 23 2005 2544 2555
59. R.S. Herbst, A.M. Maddox, M.L. Rothenberg, E.J. Small, E.H. Rubin, J. Baselga, F. Rojo, W.K. Hong, H. Swaisland, S.D. Averbuch, J. Ochs, and P.M. LoRusso Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial J. Clin. Oncol. 20 2002 3815 3825
60. R.S. Herbst, D. Prager, R. Hermann, L. Fehrenbacher, B.E. Johnson, A. Sandler, M.G. Kris, H.T. Tran, P. Klein, X. Li, D. Ramies, D.H. Johnson, and V.A. Miller TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J. Clin. Oncol. 23 2005 5892 5899
61. M. Hidalgo, L.L. Siu, J. Nemunaitis, J. Rizzo, L.A. Hammond, C. Takimoto, S.G. Eckhardt, A. Tolcher, C.D. Britten, L. Denis, K. Ferrante, D.D. Von Hoff, S. Silberman, and E.K. Rowinsky Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies J. Clin. Oncol. 19 2001 3267 3279
62. L.A. Honigberg, A.M. Smith, M. Sirisawad, E. Verner, D. Loury, B. Chang, S. Li, Z.Y. Pan, D.H. Thamm, R.A. Miller, and J.J. Buggy The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Proc. Natl. Acad. Sci. U. S. A. 107 2010 13075 13080
63. N.E. Hynes, and H.A. Lane ERBB receptors and cancer: the complexity of targeted inhibitors Nat. Rev. Cancer 5 2005 341 354
64. A. Inoue, T. Suzuki, T. Fukuhara, M. Maemondo, Y. Kimura, N. Morikawa, H. Watanabe, Y. Saijo, and T. Nukiwa Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations J. Clin. Oncol. 24 2006 3340 3346
65. D. Jackman, J. Lucca, P. Fidias, M.S. Rabin, T.J. Lynch, P. Ostler, A.T. Skarin, J. Temel, B.E. Johnson, and P.A. Jänne Phase II study of the EGFR tyrosine kinase inhibitor erlotinib in patients >70 years of age with previously untreated advanced non-small cell lung carcinoma Eur. J. Cancer Suppl. 3 2005 325 326
66. D. Jackman, W. Pao, G.J. Riely, J.A. Engelman, M.G. Kris, P.A. Jänne, T. Lynch, B.E. Johnson, and V.A. Miller Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer J. Clin. Oncol. 28 2010 357 360
67. P.A. Jänne, S.S. Ramalingam, J.C.-H. Yang, M.-J. Ahn, D.-W. Kim, S.-W. Kim, D. Planchard, Y. Ohe, E. Felip, C. Watkins, M. Cantarini, S. Ghiorghiu, and M. Ranson Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC) J. Clin. Oncol. 32 2014 8009 (abstract)
68. P.A. Jänne, J.H. Schellens, J.A. Engelman, S.G. Eckhardt, R. Millham, L.J. Denis, C.D. Britten, S.G. Wong, D.S. Boss, and D.R. Camidge Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC J. Clin. Oncol. 26 2008 8027 (abstract)
69. P.A. Jänne, J. von Pawel, R.B. Cohen, L. Crino, C.A. Butts, S.S. Olson, I.A. Eiseman, A.A. Chiappori, B.Y. Yeap, P.F. Lenehan, K. Dasse, M. Sheeran, and P.D. Bonomi Multicenter, randomized, phase II Ttrial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non-small-cell lung cancer J. Clin. Oncol. 25 2007 3936 3944
70. J.R. Jiang, H. Greulich, P.A. Jänne, W.R. Sellers, M. Meyerson, and J.D. Griffin Epidermal growth factor independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression Cancer Res. 65 2005 8968 8974
71. N. Katakami, S. Morita, H. Yoshioka, T. Seto, Y. Urata, M. Satouchi, Y. Iwamoto, K. Otsuka, N. Ikeda, T. Takahashi, H. Daga, T. Oguri, I. Goto, J. Uchida, S. Sugawara, C. Kitagawa, T. Kozuki, J. Inata, K. Nakagawa, Y. Nakanishi West Japan Oncology Group Randomized phase III study comparing gefitinib (G) with erlotinib (E) in patients (pts) with previously treated advanced lung adenocarcinoma (LA): WJOG 5108L J. Clin. Oncol. 32 2014 8041 (abstract)
72. D.-W. Kim, S.-W. Kim, T.M. Kim, S.-H. Lee, C.-M. Choi, B. Keam, J.C. Lee, D.-S. Heo, J. Lee, K.-S. Yu, I.-J. Jang, K.J. Lim, J. Son, and D.H. Lee Phase I study of HM61713, a novel epidermal growth factor receptor (EGFR) mutant selective inhibitor, in non-small cell lung cancer (NSCLC) patients having an activating EGFR mutation but failed to prior EGFR tyrosine kinase inhibitor (TKI) therapy World Conf. Lung Cancer Poster 1048 2013 (abstract)
73. D.-W. Kim, D.H. Lee, J.H. Kang, K. Park, J.-Y. Han, J.-S. Lee, I.-J. Jang, H.-Y. Kim, J. Son, and J.-H. Kim Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs) J. Clin. Oncol. 32 2014 8011 (abstract)
74. E.S. Kim, V. Hirsh, T. Mok, M.A. Socinski, R. Gervais, Y.-L. Wu, L.-Y. Li, C.L. Watkins, M.V. Sellers, E.S. Lowe, Y. Sun, M.-L. Liao, K. ∅sterlind, M. Reck, A.A. Armour, F.A. Shepherd, S.M. Lippman, and J.-Y. Douillard Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Lancet 372 2008 1809 1818
75. S.T. Kim, J.E. Uhm, J. Lee, J.M. Sun, I. Sohn, S.W. Kim, S.H. Jung, Y.H. Park, J.S. Ahn, K. Park, and M.J. Ahn Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy Lung Cancer 75 2012 82 88
76. S. Kobayashi, T.J. Boggon, T. Dayaram, P.A. Jänne, O. Kocher, M. Meyerson, B.E. Johnson, M.J. Eck, D.G. Tenen, and B. Halmos EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 352 2005 786 792
77. L. Kopper Lapatinib: a sword with two edges Pathol. Oncol. Res. 14 2008 1 8
78. T. Kosaka, Y. Yatabe, H. Endoh, H. Kuwano, T. Takahashi, and T. Mitsudomi Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications Cancer Res. 64 2004 8919 8923
79. M.G. Kris, R.B. Natale, R.S. Herbst, T.J. Lynch, D. Prager, C.P. Belani, J.H. Schiller, K. Kelly, H. Spiridonidis, A. Sandler, K.S. Albain, D. Cella, M.K. Wolf, S.D. Averbuch, J.J. Ochs, and A.C. Kay Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - a randomized trial J. Am. Med. Assoc. 290 2003 2149 2158
80. S. Krishnan, P.D. Brown, K.V. Ballman, J.B. Fiveash, J.H. Uhm, C. Giannini, K.A. Jaeckle, F.J. Geoffroy, L.B. Nabors, and J.C. Buckner Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177 Int. J. Radiat. Oncol. Biol. Phys. 65 2006 1192 1199
81. E. Kwak The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer Oncologist 16 2011 1498 1507
82. E.L. Kwak, R. Sordella, D.W. Bell, N. Godin-Heymann, R.A. Okimoto, B.W. Brannigan, P.L. Harris, D.R. Driscoll, P. Fidias, T.J. Lynch, S.K. Rabindran, J.P. McGinnis, A. Wissner, S.V. Sharma, K.J. Isselbacher, J. Settleman, and D.A. Haber Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib Proc. Natl. Acad. Sci. U. S. A. 102 2005 7665 7670
83. D. Laheru, G. Croghan, R. Bukowski, M. Rudek, W. Messersmith, C. Erlichman, R. Pelley, A. Jimeno, R. Donehower, J. Boni, R. Abbas, P. Martins, C. Zacharchuk, and M. Hidalgo A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer Clin. Cancer Res. 14 2008 5602 5609
84. H.-J. Lee, G. Schaefer, T.P. Heffron, L. Shao, X. Ye, S. Sideris, S. Malek, E. Chan, M. Merchant, H. La, S. Ubhayakar, R.L. Yauch, V. Pirazzoli, K. Politi, and J. Settleman Noncovalent wild-type-sparing inhibitors of EGFR T790M Cancer Discov. 3 2013 168 181
85. D. Leveque Pharmacokinetics of gefitinib and erlotinib Lancet Oncol. 12 2011 1093
86. W. Liang, J. Sheng, X. Wu, Y. Zhang, S. Kang, and L. Zhang Exon 19 deletion association with progression-free survival compared to L858R mutation at exon 21 in treatment with first-line EGFR-TKIs: a meta-analysis of subgroup data from eight phase III randomized controlled trials J. Clin. Oncol. 32 2014 8107 (abstract)
87. W.H. Liang, X. Wu, W.F. Fang, Y.Y. Zhao, Y.P. Yang, Z.H. Hu, C. Xue, J. Zhang, J.W. Zhang, Y.X. Ma, T. Zhou, Y. Yan, X. Hou, T. Qin, X.X. Dinglin, Y. Tian, P.Y. Huang, Y. Huang, H.Y. Zhao, and L. Zhang Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations PLOS ONE 9 2014 e85245
88. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. Brannigan, P.L. Harris, S.M. Haserlat, J.G. Supko, F.G. Haluska, D.N. Louis, D.C. Christiani, J. Settleman, and D.A. Haber Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2004 2129 2139
89. L.E. MacConaill, C.D. Campbell, S.M. Kehoe, A.J. Bass, C. Hatton, L. Niu, M. Davis, K. Yao, M. Hanna, C. Mondal, L. Luongo, C.M. Emery, A.C. Baker, J. Philips, D.J. Goff, M. Fiorentino, M.A. Rubin, K. Polyak, J. Chan, Y. Wang, J.A. Fletcher, S. Santagata, G. Corso, F. Roviello, R. Shivdasani, M.W. Kieran, K.L. Ligon, C.D. Stiles, W.C. Hahn, M.L. Meyerson, and L.A. Garraway Profiling critical cancer gene mutations in clinical tumor samples PLoS ONE 4 2009 e7887
90. M. Maemondo, A. Inoue, K. Kobayashi, S. Sugawara, S. Oizumi, H. Isobe, A. Gemma, M. Harada, H. Yoshizawa, I. Kinoshita, Y. Fujita, S. Okinaga, H. Hirano, K. Yoshimori, T. Harada, T. Ogura, M. Ando, H. Miyazawa, T. Tanaka, Y. Saijo, K. Hagiwara, S. Morita, and T. Nukiwa Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N. Engl. J. Med. 362 2010 2380 2388
91. S.J. Martins, S.R. Pais-Costa, J.F.R. Farah, R. Artigiani-Neto, and A. Goldenberg EGFR expression and prognosis in galbladder cancer Eur. J. Cancer 49 2013 639
92. R. Maruyama, Y. Nishiwaki, T. Tamura, N. Yamamoto, M. Tsuboi, K. Nakagawa, T. Shinkai, S. Negoro, F. Imamura, K. Eguchi, K. Takeda, A. Inoue, K. Tomii, M. Harada, N. Masuda, H. Jiang, Y. Itoh, Y. Ichinose, N. Saijo, and M. Fukuoka Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer J. Clin. Oncol. 26 2008 4244 4252
93. U. McDermott, S.V. Sharma, L. Dowell, P. Greninger, C. Montagut, J. Lamb, H. Archibald, R. Raudales, A. Tam, D. Lee, S.M. Rothenberg, J.G. Supko, R. Sordella, L.E. Ulkus, A.J. Iafrate, S. Maheswaran, C.N. Njauw, H. Tsao, L. Drew, J.H. Hanke, X.J. Ma, M.G. Erlander, N.S. Gray, D.A. Haber, and J. Settleman Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling Proc. Natl. Acad. Sci. U. S. A. 104 2007 19936 19941
94. V.A. Miller, V. Hirsh, J. Cadranel, Y.M. Chen, K. Park, S.W. Kim, C.C. Zhou, W.C. Su, M.Z. Wang, Y. Sun, D.S. Heo, L. Crino, E.H. Tan, T.Y. Chao, M. Shahidi, X.J. Cong, R.M. Lorence, and J.C.H. Yang Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial Lancet Oncol. 13 2012 528 538
95. T. Mitsudomi, S. Morita, Y. Yatabe, S. Negoro, I. Okamoto, J. Tsurutani, T. Seto, M. Satouchi, H. Tada, T. Hirashima, K. Asami, N. Katakami, M. Takada, H. Yoshioka, K. Shibata, S. Kudoh, E. Shimizu, H. Saito, S. Toyooka, K. Nakagawa, M. Fukuoka, and W.J.O. Grp Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol. 11 2010 121 128
96. T. Mitsudomi, and Y. Yatabe Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer Cancer Sci. 98 2007 1817 1824
97. T.S. Mok, Y.L. Wu, S. Thongprasert, C.H. Yang, D.T. Chu, N. Saijo, P. Sunpaweravong, B.H. Han, B. Margono, Y. Ichinose, Y. Nishiwaki, Y. Ohe, J.J. Yang, B. Chewaskulyong, H.Y. Jiang, E.L. Duffield, C.L. Watkins, A.A. Armour, and M. Fukuoka Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N. Engl. J. Med. 361 2009 947 957
98. T.S.K. Mok, K. Nakagawa, R. Rosell, Y.L. Wu, C. Trygstad, R. Capizzi, R. DeBenedetto, Z. Goldberg, T. Wang, and V. Antic Phase 3 randomized study (Archer 1050) of 1st-line dacomitinib vs gefitinib for advanced NSCLC with EGFR mutation(S) Ann. Oncol. 24 2013 138 (abstract)
99. J.D. Moyer, E.G. Barbacci, K.K. Iwata, L. Arnold, B. Boman, A. Cunningham, C. DiOrio, J. Doty, M.J. Morin, M.P. Moyer, M. Neveu, V.A. Pollack, L.R. Pustilnik, M.M. Reynolds, D. Sloan, A. Theleman, and P. Miller Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase Cancer Res. 57 1997 4838 4848
100. T. Mukohara, J.A. Engelman, N.H. Hanna, B.Y. Yeap, S. Kobayashi, N. Lindeman, B. Halmos, J. Pearlberg, Z. Tsuchihashi, L.C. Cantley, D.G. Tenen, B.E. Johnson, and P.A. Jaenne Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations J. Natl. Cancer Inst. 97 2005 1185 1194
101. J. Nagasawa, A. Mizokami, K. Koshida, S. Yoshida, K. Naito, and M. Namiki Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo Int. J. Urol. 13 2006 587 592
102. J. Nemunaitis, I. Eiseman, C. Cunningham, N. Senzer, A. Williams, P.F. Lenehan, S.C. Olson, P. Bycott, M. Schlicht, R. Zentgraff, D.M. Shin, and R.G. Zinner Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer Clin. Cancer Res. 11 2005 3846 3853
103. K. Ohashi, L.V. Sequist, M.E. Arcila, T. Moran, J. Chmielecki, Y.L. Lin, Y.M. Pan, L. Wang, E. de Stanchina, K. Shien, K. Aoe, S. Toyooka, K. Kiura, L. Fernandez-Cuesta, P. Fidias, J.C.H. Yang, V.A. Miller, G.J. Riely, M.G. Kris, J.A. Engelman, C.L. Vnencak-Jones, D. Dias-Santagata, M. Ladanyi, and W. Pao Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1 Proc. Natl. Acad. Sci. U. S. A. 109 2012 E2127 E2133
104. J.G. Paez, P.A. Jänne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, T.J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M.J. Eck, W.R. Sellers, B.E. Johnson, and M. Meyerson EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
105. H. Pan, R. Liu, S. Li, H. Fang, Z. Wang, S. Huang, and J. Zhou Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes Cell Biochem. Biophys. 70 2014 553 558
106. Z.Y. Pan, H. Scheerens, S.J. Li, B.E. Schultz, P.A. Sprengeler, L.C. Burrill, R.V. Mendonca, M.D. Sweeney, K.C.K. Scott, P.G. Grothaus, D.A. Jeffery, J.M. Spoerke, L.A. Honigberg, P.R. Young, S.A. Dalrymple, and J.T. Palmer Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase Chemmedchem 2 2007 58 61
107. W. Pao, and J. Chmielecki Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer Nat. Rev. Cancer 10 2010 760 774
108. W. Pao, and N. Girard New driver mutations in non-small-cell lung cancer Lancet Oncol. 12 2011 175 180
109. W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, D. Kupfer, R. Wilson, M. Kris, and H. Varmus EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc. Natl. Acad. Sci. U. S. A. 101 2004 13306 13311
110. W. Pao, V.A. Miller, K.A. Politi, G.J. Riely, R. Somwar, M.F. Zakowski, M.G. Kris, and H. Varmus Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med. 2 2005 225 235
111. J.H. Park, Y.T. Liu, M.A. Lemmon, and R. Radhakrishnan Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain Biochem. J. 448 2012 417 423
112. F. Penault-Llorca, X. Durando, and J.O. Bay EGFR and cancer prognosis Bull. Cancer (Paris) 90 2003 192 196
113. Ramalingam Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer (vol. 30, pg 3337, 2012) J. Clin. Oncol. 31 2013 399
114. S.S. Ramalingam, F. Blackhall, M. Krzakowski, C.H. Barrios, K. Park, I. Bover, D.S. Heo, R. Rosell, D.C. Talbot, R. Frank, S.P. Letrent, A. Ruiz-Garcia, I. Taylor, J.Q. Liang, A.K. Campbell, J. O'Connell, and M. Boyer Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer J. Clin. Oncol. 30 2012 3337 3344
115. M. Ranson, L.A. Hammond, D. Ferry, M. Kris, A. Tullo, P.I. Murray, V. Miller, S. Averbuch, J. Ochs, C. Morris, A. Feyereislova, H. Swaisland, and E.K. Rowinsky ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial J. Clin. Oncol. 20 2002 2240 2250
116. N. Rekhtman, M. He, C. Lau, K. Nafa, G.J. Riely, M.F. Zakowski, and M. Ladanyi Analysis of EGFR and KRAS mutations in high-grade neuroendocrine carcinomas of the lung Lab. Invest. 89 2009 360
117. G.W. Rewcastle, B.D. Palmer, A.J. Bridges, H.D.H. Showalter, S. Li, J. Nelson, A. McMichael, A.J. Kraker, D.W. Fry, and W.A. Denny Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor J. Med. Chem. 39 1996 918 928
118. G.W. Rewcastle, B.D. Palmer, A.M. Thompson, A.J. Bridges, D.R. Cody, H.R. Zhou, D.W. Fry, A. McMichael, and W.A. Denny Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP-binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor J. Med. Chem. 39 1996 1823 1835
119. R. Rosell, E. Carcereny, R. Gervais, A. Vergnenegre, B. Massuti, E. Felip, R. Palmero, R. Garcia-Gomez, C. Pallares, J.M. Sanchez, R. Porta, M. Cobo, P. Garrido, F. Longo, T. Moran, A. Insa, F. De Marinis, R. Corre, I. Bover, A. Illiano, E. Dansin, J. de Castro, M. Milella, N. Reguart, G. Altavilla, U. Jimenez, M. Provencio, M.A. Moreno, J. Terrasa, J. Munoz-Langa, J. Valdivia, D. Isla, M. Domine, O. Molinier, J. Mazieres, N. Baize, R. Garcia-Campelo, G. Robinet, D. Rodriguez-Abreu, G. Lopez-Vivanco, V. Gebbia, L. Ferrera-Delgado, P. Bombaron, R. Bernabe, A. Bearz, A. Artal, E. Cortesi, C. Rolfo, M. Sanchez-Ronco, A. Drozdowskyj, C. Queralt, I. de Aguirre, J.L. Ramirez, J.J. Sanchez, M.A. Molina, M. Taron, L. Paz-Ares, G.F. Pneumocancerologie, and A.I.O. Toracica Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol. 13 2012 239 246
120. R. Rosell, T. Moran, C. Queralt, R. Porta, F. Cardenal, C. Camps, M. Majem, G. Lopez-Vivanco, D. Isla, M. Provencio, A. Insa, B. Massuti, J.L. Gonzalez-Larriba, L. Paz-Ares, I. Bover, R. Garcia-Campelo, M.A. Moreno, S. Catot, C. Rolfo, N. Reguart, R. Palmero, J.M. Sanchez, R. Bastus, C. Mayo, J. Bertran-Alamillo, M.A. Molina, J.J. Sanchez, M. Taron, and S.L.C. Grp Screening for epidermal growth factor receptor mutations in lung cancer N. Engl. J. Med. 361 2009 958 967
121. R. Roskoski Jr. The ErbB/HER family of protein-tyrosine kinases and cancer Pharmacol. Res. 79 2014 34 74
122. Q. Ryan, A. Ibrahim, M.H. Cohen, J. Johnson, C.W. Ko, R. Sridhara, R. Justice, and R. Pazdur FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2 Oncologist 13 2008 1114 1119
123. L.V. Sequist, B. Besse, T.J. Lynch, V.A. Miller, K.K. Wong, B. Gitlitz, K. Eaton, C. Zacharchuk, A. Freyman, C. Powell, R. Ananthakrishnan, S. Quinn, and J.C. Soria Neratinib, an irreversible Pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer J. Clin. Oncol. 28 2010 3076 3083
124. L.V. Sequist, R.S. Heist, A.T. Shaw, P. Fidias, J.S. Temel, I.T. Lennes, E. Bast, B.A. Waltman, M. Lanuti, A. Muzikansky, M. Mino-Kenudson, A.J. Iafrate, D.R. Borger, D. Dias-Santagata, and J.A. Engelman SNaPshot genotyping of non-small cell lung cancers (NSCLC) in clinical practice J. Clin. Oncol. 29 2011 7518 (abstract)
125. L.V. Sequist, R.G. Martins, D. Spigel, S.M. Grunberg, A. Spira, P.A. Jaenne, V.A. Joshi, D. McCollum, T.L. Evans, A. Muzikansky, G.L. Kuhlmann, M. Han, J.S. Goldberg, J. Settleman, A.J. Iafrate, J.A. Engelman, D.A. Haber, B.E. Johnson, and T.J. Lynch First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations J. Clin. Oncol. 26 2008 2442 2449
126. L.V. Sequist, J.-C. Soria, S.M. Gadgeel, H.A. Wakelee, D.R. Camidge, A. Varga, B.J. Solomon, V. Papadimitrakopoulou, S.S. Jaw-Tsai, L. Caunt, P. Kaur, L. Rolfe, A.R. Allen, and J.W. Goldman First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M) J. Clin. Oncol. 32 2014 8010 (abstract)
127. L.V. Sequist, J.C.H. Yang, N. Yamamoto, K. O'Byrne, V. Hirsh, T. Mok, S.L. Geater, S. Orlov, C.M. Tsai, M. Boyer, W.C. Su, J. Bennouna, T. Kato, V. Gorbunova, K.H. Lee, R. Shah, D. Massey, V. Zazulina, M. Shahidi, and M. Schuler Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations J. Clin. Oncol. 31 2013 3327 3334
128. S.V. Sharma, D.W. Bell, J. Settleman, and D.A. Haber Epidermal growth factor receptor mutations in lung cancer Nat. Rev. Cancer 7 2007 169 181
129. F.A. Shepherd, J.R. Pereira, T. Ciuleanu, E.H. Tan, V. Hirsh, S. Thongprasert, D. Campos, S. Maoleekoonpiroj, M. Smylie, R. Martins, M. van Kooten, M. Dediu, B. Findlay, D.S. Tu, D. Johnston, A. Bezjak, G. Clark, P. Santabarbara, L. Seymour, and N.C.I.C.C. Trials Erlotinib in previously treated non-small-cell lung cancer N. Engl. J. Med. 353 2005 123 132
130. Y. Shi, L. Zhang, X. Liu, C. Zhou, S. Zhang, D. Wang, Q. Li, S. Qin, C. Hu, Y. Zhang, J. Chen, Y. Cheng, J. Feng, H. Zhang, Y. Song, Y.-L. Wu, N. Xu, J. Zhou, R. Luo, C. Bai, Y. Jin, W. Liu, Z. Wei, F. Tan, Y. Wang, L. Ding, H. Dai, S. Jiao, J. Wang, L. Liang, W. Zhang, and Y. Sun Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial Lancet Oncol. 14 2013 953 961
131. K. Shien, S. Toyooka, H. Yamamoto, J. Soh, M. Jida, K.L. Thu, S. Hashida, Y. Maki, E. Ichihara, H. Asano, K. Tsukuda, N. Takigawa, K. Kiura, A.F. Gazdar, W.L. Lam, and S. Miyoshi Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells Cancer Res. 73 2013 3051 3061
132. F.M. Sirotnak, M.F. Zakowski, V.A. Miller, H.I. Scher, and M.G. Kris Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase Clin. Cancer Res. 6 2000 4885 4892
133. R.T.T. Sjin, K. Lee, A.O. Walter, A. Dubrovskiy, M. Sheets, T.S. Martin, M.T. Labenski, Z. Zhu, R. Tester, R. Karp, A. Medikonda, P. Chaturvedi, Y. Ren, H. Haringsma, J. Etter, M. Raponi, A.D. Simmons, T.C. Harding, D. Niu, M. Nacht, W.F. Westlin, R.C. Petter, A. Allen, and J. Singh In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing Mol. Cancer Ther. 13 2014 1468 1479
134. J.B. Smaill, G.W. Rewcastle, J.A. Loo, K.D. Greis, O.H. Chan, E.L. Reyner, E. Lipka, H.D.H. Showalter, P.W. Vincent, W.L. Elliott, and W.A. Denny Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)quinazoline- and 4-(phenylamino)pyrido[3, 2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions J. Med. Chem. 43 2000 1380 1397
135. F. Solca, G. Dahl, A. Zoephel, G. Bader, M. Sanderson, C. Klein, O. Kraemer, F. Himmelsbach, E. Haaksma, and G.R. Adolf Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker J. Pharmacol. Exp. Ther. 343 2012 342 350
136. R. Sordella, D.W. Bell, D.A. Haber, and J. Settleman Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways Science 305 2004 1163 1167
137. S.S. Sridhar, L. Seymour, and F.A. Shepherd Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer Lancet Oncol. 4 2003 397 406
138. J. Stamos, M.X. Sliwkowski, and C. Eigenbrot Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor J. Biol. Chem. 277 2002 46265 46272
139. K. Takezawa, V. Pirazzoli, M.E. Arcila, C.A. Nebhan, X.L. Song, E. de Stanchina, K. Ohashi, Y.Y. Janjigian, P.J. Spitzler, M.A. Melnick, G.J. Riely, M.G. Kris, V.A. Miller, M. Ladanyi, K. Politi, and W. Pao HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFR(T790M) mutation Cancer Discov. 2 2012 922 933
140. F. Tan, X. Shen, D. Wang, G. Xie, X. Zhang, L. Ding, Y. Hu, W. He, Y. Wang, and Y. Wang Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies Lung Cancer 76 2012 177 182
141. N. Thatcher, A. Chang, P. Parikh, J.R. Pereira, T. Ciuleanu, J. von Pawel, S. Thongprasert, E.H. Tan, K. Pemberton, V. Archer, and K. Carroll Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (iressa survival evaluation in lung cancer) Lancet 366 2005 1527 1537
142. A.M. Thompson, A.J. Bridges, D.W. Fry, A.J. Kraker, and W.A. Denny Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)pyrido[4, 3-D]pyrimidines and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-D]pyrimidines - a new class of inhibitors of the tyrosine kinase-activity of the epidermal growth-factor receptor J. Med. Chem. 38 1995 3780 3788
143. K. Thornton, G. Kim, V.E. Maher, S. Chattopadhyay, S.H. Tang, Y.J. Moon, P.F. Song, A. Marathe, S. Balakrishnan, H. Zhu, C. Garnett, Q. Liu, B. Booth, B. Gehrke, R. Dorsam, L. Verbois, D. Ghosh, W. Wilson, J. Duan, H. Sarker, S.P. Miksinski, L. Skarupa, A. Ibrahim, R. Justice, A. Murgo, and R. Pazdur Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary Clin. Cancer Res. 18 2012 3722 3730
144. A.L. Visbal, B.A. Williams, F.C. Nichols, R.S. Marks, J.R. Jett, M.C. Aubry, E.S. Edell, J.A. Wampfler, J.R. Molina, and P. Yang Gender differences in non-small-cell lung cancer survival: an analysis of 4618 patients diagnosed between 1997 and 2002 Ann. Thorac. Surg. 78 2004 209 215
145. B.R. Voldborg, L. Damstrup, M. Spang-Thomsen, and H.S. Poulsen Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials Ann. Oncol. 8 1997 1197 1206
146. A.E. Wakeling, S.P. Guy, J.R. Woodburn, S.E. Ashton, B.J. Curry, A.J. Barker, and K.H. Gibson ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy Cancer Res. 62 2002 5749 5754
147. A.O. Walter, R.T.T. Sjin, H.J. Haringsma, K. Ohashi, J. Sun, K. Lee, A. Dubrovskiy, M. Labenski, Z. Zhu, Z. Wang, M. Sheets, T. St Martin, R. Karp, D. van Kalken, P. Chaturvedi, D. Niu, M. Nacht, R.C. Petter, W. Westlin, K. Lin, S. Jaw-Tsai, M. Raponi, T. Van Dyke, J. Etter, Z. Weaver, W. Pao, J. Singh, A.D. Simmons, T.C. Harding, and A. Allen Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC Cancer Discov. 3 2013 1404 1415
148. Z.H. Wang, P.A. Longo, M.K. Tarrant, K. Kim, S. Head, D.J. Leahy, and P.A. Cole Mechanistic insights into the activation of oncogenic forms of EGF receptor Nat. Struct. Mol. Biol. 18 2011 1388 1394
149. H. Wao, R. Mhaskar, A. Kumar, B. Miladinovic, and B. Djulbegovic Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis Syst. Rev. 2 2013 1 11
150. R.A. Ward, M.J. Anderton, S. Ashton, P.A. Bethel, M. Box, S. Butterworth, N. Colclough, C.G. Chorley, C. Chuaqui, D.A.E. Cross, L.A. Dakin, J.É. Debreczeni, C. Eberlein, M.R.V. Finlay, G.B. Hill, M. Grist, T.C.M. Klinowska, C. Lane, S. Martin, J.P. Orme, P. Smith, F. Wang, and M.J. Waring Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR) J. Med. Chem. 56 2013 7025 7048
151. W.H.J. Ward, P.N. Cook, A.M. Slater, D.H. Davies, G.A. Holdgate, and L.R. Green Epidermal growth-factor receptor tyrosine kinase - investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor Biochem. Pharmacol. 48 1994 659 666
152. S.R. Wedge, D.J. Ogilvie, M. Dukes, J. Kendrew, R. Chester, J.A. Jackson, S.J. Boffey, P.J. Valentine, J.O. Curwen, H.L. Musgrove, G.A. Graham, G.D. Hughes, A.P. Thomas, E.S.E. Stokes, B. Curry, G.H.P. Richmond, P.F. Wadsworth, A.L. Bigley, and L.F. Hennequin ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Res. 62 2002 4645 4655
153. I.B. Weinstein Cancer: addiction to oncogenes - the Achilles heal of cancer Science 297 2002 63 64
154. K.K. Wong, P.M. Fracasso, R.M. Bukowski, T.J. Lynch, P.N. Munster, G.I. Shapiro, P.A. Jaenne, J.P. Eder, M.J. Naughton, M.J. Ellis, S.F. Jones, T. Mekhail, C. Zacharchuk, J. Vermette, R. Abbas, S. Quinn, C. Powell, and H.A. Burris A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors Clin. Cancer Res. 15 2009 2552 2558
155. J.Y. Wu, S.G. Wu, C.H. Yang, Y.L. Chang, Y.C. Chang, Y.C. Hsu, J.Y. Shih, and P.C. Yang Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations Lung Cancer 72 2011 205 212
156. E. Wyluda, K. Newport, M. Sauder, and S. Sivendran Safety and efficacy of vandetanib in the treatment of medullary thyroid cancer J. Symptoms Signs 3 2014 83 90
157. W.L. Xia, L.H. Liu, P. Ho, and N.L. Spector Truncated ErbB2 receptor (p95(ErbB2)) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016 Oncogene 23 2004 646 653
158. G. Yang, Y. Yao, J. Zhou, and Q. Zhao Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer Oncol. Rep. 27 2012 2066 2072
159. J.C. Yang, D. Kim, D. Planchard, Y. Ohe, S.S. Ramalingam, M. Ahn, S. Kim, W. Su, L. Horn, D. Haggstrom, E. Felip, J. Kim, P. Frewer, M. Cantarini, S. Ghiorghiu, M. Ranson, and P.A. Jänne Updated safety and efficacy from a phase I study of AZD9291 in patients (pts) with EGFR-TKI-resistant non-small cell lung cancer (NSCLC) Ann. Oncol. 25 2014 449PD (abstract)
160. J.C.H. Yang, M.H. Schuler, N. Yamamoto, K.J. O'Byrne, V. Hirsh, T. Mok, S.L. Geater, S.V. Orlov, C.M. Tsai, M.J. Boyer, W.C. Su, J. Bennouna, T. Kato, V. Gorbunova, K.H. Lee, R.N.H. Shah, D. Massey, R.M. Lorence, M. Shahidi, and L.V. Sequist LUX-Lung 3: a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations J. Clin. Oncol. 30 2012 LBA7500 (abstract)
161. J.C.H. Yang, J.Y. Shih, W.C. Su, T.C. Hsia, C.M. Tsai, S.H.I. Ou, C.J. Yu, G.C. Chang, C.L. Ho, L.V. Sequist, A.Z. Dudek, M. Shahidi, X.J. Cong, R.M. Lorence, P.C. Yang, and V.A. Miller Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial Lancet Oncol. 13 2012 539 548
162. T.A. Yap, L. Vidal, J. Adam, P. Stephens, J. Spicer, H. Shaw, J. Ang, G. Temple, S. Bell, M. Shahidi, M. Uttenreuther-Fischer, P. Stopfer, A. Futreal, H. Calvert, J.S. de Bono, and R. Plummer Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors J. Clin. Oncol. 28 2010 3965 3972
163. K. Yoshida, Y. Yatabe, J.Y. Park, J. Shimizu, Y. Horio, K. Matsuo, T. Kosaka, T. Mitsudomi, and T. Hida Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer J. Thorac. Oncol. 2 2007 22 28
164. S. Yoshikawa, M. Kukimoto-Niino, L. Parker, N. Handa, T. Terada, T. Fujimoto, Y. Terazawa, M. Wakiyama, M. Sato, S. Sano, T. Kobayashi, T. Tanaka, L. Chen, Z.J. Liu, B.C. Wang, M. Shirouzu, S. Kawa, K. Semba, T. Yamamoto, and S. Yokoyama Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor Oncogene 32 2013 27 38
165. H.A. Yu, M.E. Arcila, N. Rekhtman, C.S. Sima, M.F. Zakowski, W. Pao, M.G. Kris, V.A. Miller, M. Ladanyi, and G.J. Riely Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers Clin. Cancer Res. 19 2013 2240 2247
166. C.-H. Yun, T.J. Boggon, Y. Li, M.S. Woo, H. Greulich, M. Meyerson, and M.J. Eck Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity Cancer Cell 11 2007 217 227
167. C.H. Yun, K.E. Mengwasser, A.V. Toms, M.S. Woo, H. Greulich, K.K. Wong, M. Meyerson, and M.J. Eck The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proc. Natl. Acad. Sci. U. S. A. 105 2008 2070 2075
168. M.F. Zakowski, M. Ladanyi, M.G. Kris Memorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome Group EGFR mutations in small-cell lung cancers in patients who have never smoked N. Engl. J. Med. 355 2006 213 215
169. Q. Zhao, J. Shentu, N. Xu, J. Zhou, G. Yang, Y. Yao, F. Tan, D. Liu, Y. Wang, and J. Zhou Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors Lung Cancer 73 2011 195 202
170. C.C. Zhou, Y.L. Wu, G.Y. Chen, J.F. Feng, X.Q. Liu, C.L. Wang, S.C. Zhang, J. Wang, S.W. Zhou, S.X. Ren, S. Lu, L. Zhang, C.P. Hu, C.H. Hu, Y. Luo, L. Chen, M. Ye, J.N. Huang, X.Y. Zhi, Y.P. Zhang, Q.Y. Xiu, J. Ma, L. Zhang, and C.X. You Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol. 12 2011 735 742
171. W. Zhou, D. Ercan, L. Chen, C.-H. Yun, D. Li, M. Capelletti, A.B. Cortot, L. Chirieac, R.E. Iacob, R. Padera, J.R. Engen, K.-K. Wong, M.J. Eck, N.S. Gray, and P.A. Jänne Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Nature 462 2009 1070 1074